Galmed PharmaceuticalsEOCN
13F holders, Q4 2024 (December 31)12holders +2
2new positions
1sold out
$3.19avg. 13F price*
At the end of Q4 2024, 12 institutions reported holding Galmed Pharmaceuticals Ltd. (EOCN) in their 13F filings, up 2 from Q3 2024. 2 opened new positions and 1 sold out. The largest holders were Schonfeld Strategic Advisors LLC ($81K), Morgan Stanley ($40K) and UBS Group AG ($21K).
- Company
- Galmed Pharmaceuticals Ltd.
- CUSIP
- M47238148
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $81K |
| Exits | 1 | $7 |
All 13F filers, Q3 2024 → Q4 2024: 39,281 shares bought and 115 shares sold, net +39,166 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 12 holders
| Schonfeld Strategic Advisors LLC | 0.00% | New | 25,400 | $81K |
| Morgan Stanley | 0.00% | Add +11948.1% | 12,530 | $40K |
| UBS Group AG | 0.00% | Add +27.6% | 6,721 | $21K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -65.9% | 59 | $188 |
| Wells Fargo & Company | 0.00% | No change | 18 | $57 |
| SBI Securities Co., Ltd. | 0.00% | — | 16 | $51 |
| Federation des caisses Desjardins du Quebec | 0.00% | No change | 14 | $45 |
| Osaic Holdings, Inc. | 0.00% | No change | 5 | $15 |
| Allworth Financial LP | 0.00% | No change | 2 | $6 |
| Elevation Wealth Partners, LLC | 0.00% | No change | 1 | $4 |
| Dogwood Wealth Management LLC | 0.00% | New | 1 | $3 |
| Tsfg, LLC | 0.00% | No change | 17 | $0 |
"% of holder's portfolio" is EOCN's weight in each manager's 13F, not the share of Galmed Pharmaceuticals Ltd. the manager owns.